obesity
Conditions
Interventions
As an intervention, a personalized cooling protocol will be used in order to
activate BAT and induce non-shivering thermogenesis. During the cooling
procedure, subjects will be exposed to mild cold
Sponsors
Interne Geneeskunde, sectie Endocrinologie
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Dutch white Caucasian males or females - Age: 18-35 years - Lean group: BMI * 18 and * 25 kg/m2 - Obese glucose tolerant group: BMI * 30 and * 42 kg/m2 and fasted plasma glucose levels
Exclusion criteria
Exclusion criteria: - Diabetes mellitus (determined on basis of fasting glucose or OGTT defined by ADA criteria - Any other active endocrine disease (thyroid disease, any signs of Cushing*s syndrome, adrenal disease and lipid-associated disorders such as familial hypercholesterolemia) - Any chronic renal or hepatic disease - Use of medication known to influence glucose and/or lipid metabolism or brown fat activity (e.g. beta blockers, antidepressants) - Smoking - Abuse of alcohol or other substances - Pregnancy - Disturbed day-night rhythm such as working night shifts or having a jet lag (participation is allowed 6 weeks after the last night shift or 6 weeks after arriving from another time zone) - Participation in an intensive weight-loss program or vigorous exercise program during the last year before the start of the study - Current participation in another research projects that may influence the current research project - Clinically relevant abnormalities in clinical chemistry at screening (to be judged by the study physician)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cold-induced non-shivering thermogenesis/EE (as measured by indirect calorimetry) | — |
Secondary
| Measure | Time frame |
|---|---|
| Cold-induced changes in: - supraclavicular skin temperature (as measured with iButtons and thermography) - serum markers for lipid metabolism (TC, HDL-C, LDL-C, TG, free fatty acids) and dynamic changes in lipoproteins. - serum markers for sympathetic output (norepinephrine, epinephrine) - primary and secondary endpoints between lean and obese subjects | — |
Countries
Netherlands
Outcome results
None listed